Design: Multicentric and randomized, phase 1
Status: Start expected in March 2023
Study duration per participant: up to 36 weeks
Study Title: « A prophylactic HIV vaccination trial to evaluate the safety and immunogenicity of a DREP vaccine against HIV Clade C alone and in combination with a Clade C Env protein in healthy HIV-uninfected adults.»
In this study, we will investigate the safety, tolerability and immune response of a new vaccine called DREP-HIV-PT1 (DREP). We are trying to find out if the vaccine is safe to give to people and if it does not cause too much discomfort. We also want to know if the DREP vaccine is able to stimulate the immune system when combined with other experimental vaccines already studued in clinical trials.